CRISPR-Cas Liver Targeting via AAV Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome editing technologies, such as CRISPR-Cas systems, face challenges in achieving efficient and specific targeting of genetic sequences in eukaryotic genomes, particularly in liver tissues, requiring improved delivery methods and reduced toxicity for therapeutic applications.
Innovation Solution
The development of a CRISPR-Cas system with optimized guide RNAs and chimeric Cas9 enzymes, including mutations in catalytic domains, for enhanced specificity and reduced toxicity, combined with delivery vectors like AAV2/8 for targeted gene editing in liver cells, allowing for precise modification and therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CRISPR-Cas systems are used for genome editing in liver tissues, then gene editing capability is improved, but delivery efficiency and tissue specificity are insufficient
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediary carriers to deliver CRISPR-Cas components to liver tissues. The AAV vector serves as a mediator between the CRISPR-Cas system and target cells, enabling efficient transduction and sustained expression of editing components while maintaining safety through non-integrating genome delivery mechanisms
Solution Approach 2:
The patent employs liver-specific promoters (such as albumin promoter) and tissue-specific delivery strategies to concentrate CRISPR-Cas activity specifically in hepatocytes. This localizes the editing function to the target tissue while minimizing exposure to other organs, thereby improving delivery efficiency to liver tissues and reducing off-target effects
2Manufacturing precision
If CRISPR-Cas systems are used for therapeutic applications, then gene editing precision is improved, but toxicity and off-target effects increase
Solution Approach 1:
The patent separates the CRISPR-Cas system into distinct modular components (Cas9 enzyme, guide RNA, and optional donor DNA templates) that can be independently optimized and delivered. This segmentation allows for tailored design where high-fidelity Cas9 variants with reduced off-target activity can be combined with precise guide RNAs, improving editing precision while minimizing toxicity through controlled expression of each component
Solution Approach 2:
The patent utilizes engineered high-fidelity Cas9 variants with modified amino acid sequences that alter the enzyme's DNA binding characteristics. These parameter changes in the Cas9 protein structure enhance specificity for target sequences and reduce non-specific binding, thereby improving gene editing precision while decreasing off-target effects and associated toxicity
3Adaptability or versatility
If CRISPR-Cas systems are used for in vivo editing, then therapeutic potential is improved, but delivery complexity and manufacturing difficulty increase
Solution Approach 1:
The patent combines multiple CRISPR-Cas functional elements (Cas9 coding sequence, guide RNA expression cassettes, and regulatory elements) into a single integrated AAV vector construct. This merging simplifies the delivery system by consolidating multiple components into one manufacturable viral vector, reducing delivery complexity while maintaining the therapeutic potential for in vivo genome editing applications
Data Source
AI summary
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues of organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provide dare methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.